Physician profile
Raven Ladner
NPI 1740549781
$3,514.54
in general payments reported to CMS, 2019-2025
30 companies · $846 in 2025
The $846 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $623 · 2020: $178 · 2021: $374 · 2022: $640 · 2023: $423 · 2024: $430 · 2025: $846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,699.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $592.41 | 2020-2025 | |
| Pfizer INC. | $446.11 | 2021-2025 | |
| Lilly USA, LLC | $389.70 | 2020-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $277.52 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $234.67 | 2019-2025 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.24 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $182.77 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $162.83 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $111.21 | 2019-2022 | |
| Novo Nordisk INC | $108.93 | 2019-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $106.53 | 2022-2025 | |
| Abbott Laboratories | $95.19 | 2023-2025 | Freestyle Libre |
| Amarin Pharma, INC. | $77.80 | 2020-2021 | |
| Scilex Pharmaceuticals INC. | $72.59 | 2019 | |
| Merck Sharp & Dohme LLC | $61.31 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $51.72 | 2023-2025 | Gemtesa |
| Astellas Pharma US INC | $46.58 | 2025 | Veozah |
| Genzyme Corporation | $41.42 | 2019 | |
| Phathom Pharmaceuticals, INC. | $41.22 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $37.57 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $25.08 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $23.55 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.46 | 2025 | Rexulti |
| Csl Behring | $17.89 | 2019 | |
| Xeris Pharmaceuticals, INC. | $17.24 | 2023 | Gvoke Hypopen |
| Exact Sciences Corporation | $17.16 | 2025 | Cologuard Collection Kit |
| Genentech USA, INC. | $16.60 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.21 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.68 | 2022 | |
| Hikma Pharmaceuticals USA | $13.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raven Ladner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.